|Bid||141.71 x 800|
|Ask||141.75 x 800|
|Day's Range||140.87 - 144.00|
|52 Week Range||81.79 - 169.14|
|Beta (5Y Monthly)||1.33|
|PE Ratio (TTM)||130.19|
|Earnings Date||Jul 22, 2020 - Jul 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||158.12|
IQVIA™ (NYSE: IQV) today announced its strategic alliance with LMC Manna Research, the largest network of fully owned and integrated clinical research sites in Canada, to launch IQVIA’s first Prime Site in Canada. This adds to our network of more than 980 Prime and Partner clinical sites globally, which are sites with special designation assuring pharmaceutical and biotech companies their clinical trials will take place in premier investigative research centers with recognized professionals and with infrastructure focused on innovation and research development for patients.
Moody's Investors Service ("Moody's") assigned a Ba3 rating to the proposed senior unsecured notes of IQVIA Inc. ("IQVIA"). There are no changes to IQVIA's existing ratings, including the Ba2 Corporate Family Rating, Ba2-PD Probability of Default Rating, and SGL-1 Speculative Grade Liquidity Rating. Use of proceeds from the notes offering will include refinancing existing unsecured notes and a partial repayment of revolver borrowings.
Q2 Solutions, a leading clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, today announced its partnership with Thermo Fisher Scientific to use the Ion Torrent Genexus System, the first fully integrated, next-generation sequencing (NGS) platform, to deliver clinical trial lab results economically with unprecedented speed.
Solid technological suite and growth opportunities from emerging markets are positives for IQVIA Holdings (IQV). However, higher interest expense, seasonality and foreign exchange rate risks persist.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
IQVIA™ (NYSE: IQV) today announced the launch of HCP/O Engagement Management, the industry’s first end-to-end, orchestrated healthcare professional/organization (HCP/O) solution that enables the planning, management, contracting, and payment of HCP/Os globally.
IQVIA™ (NYSE: IQV) today announced that the Walter and Eliza Hall Institute of Medical Research, a leading biomedical research organization in Australia, has selected IQVIA to manage COVID SHIELD, a Phase II/III randomized, double-blinded clinical study of preventive care for frontline healthcare workers fighting the COVID-19 pandemic.
It's been a pretty great week for IQVIA Holdings Inc. (NYSE:IQV) shareholders, with its shares surging 11% to US$143...
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, has joined the ACCORD-2 collaboration, which will fast-track development of new treatments for COVID-19. IQVIA will provide a single research platform across the United Kingdom to facilitate multiple clinical trials regardless of sponsor. This strategic alliance will examine the effectiveness of repurposed medicines, potential new drugs, and unlicensed therapies for treating COVID-19 patients.
With me on the call today are Ari Bousbib, Chairman and Chief Executive Officer; Michael McDonnell, Executive Vice President and Chief Financial Officer; Eric Sherbet, Executive Vice President and General Counsel; Nick Childs, Senior Vice President, Financial Planning and Analysis; and Jen Halchak, Senior Director, Investor Relations. Today, we will be referencing a presentation that will be visible during this call for those of you on our webcast.
Shares of IQVIA Holdings (NYSE:IQV) rose 1.3% after the company reported Q1 results.Quarterly Results Earnings per share decreased 1.96% over the past year to $1.50, which beat the estimate of $1.48.Revenue of $2,754,000,000 up by 2.61% from the same period last year, which beat the estimate of $2,720,000,000.Guidance Q2 EPS expected to be between $1.00 and $1.14.Q2 revenue expected to be between $2,365,000,000 and $2,440,000,000.Conference Call Details Date: Apr 28, 2020View more earnings on IQVTime: 10:05 AM ETWebcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.iqvia.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2160215&sessionid=1&key=F113A19EF878954541CB973E5F79F55A®Tag=&sourcepage=registerTechnicals 52-week high: $169.14Company's 52-week low was at $81.79Price action over last quarter: down 19.23%Company Overview IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The CRO segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The legacy IMS business provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers.See more from Benzinga * Sirius XM Holdings: Q1 Earnings Insights * TE Connectivity: Q2 Earnings Insights * Recap: Cummins Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced the launch of its COVID Active Research Experience (CARE) Project at helpstopcovid19.com. The IQVIA CARE Project is an opt-in registry available to anyone – to advance understanding of COVID-19 through shared information about disease prevalence, symptom progression, and treatment outcomes.
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced its new technology-enabled COVID-19 Trial Matching Tool at c19trials.com, which is one of the world’s first online platforms that matches individuals with specific COVID-19 studies to accelerate clinical research projects.
One of the Triangle's largest contract research organizations (CRO) has updated its previous guidance regarding the impact of COVID-19, saying it will cost the company millions more than expected.
ObvioHealth, a digital research company, announces the launch of a registry to monitor COVID-19 prevalence, symptoms and immune response in the United States over the coming 12 months.